Clinical trials

2

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Efficacy and Safety of Ultra_HYPofractionated RadiotHerapy in Women With BrEast CaNcer Receiving Regional Nodal Radiation vs Nodal Moderate Hypofractionated Radiotherapy

The reduction in the number of fractions in radiotherapy is especially attractive in several senses, and even more so considering breast cancer, which has a high incidence and generally favorable prognosis. Thus, as a reference Institution, the investigators intend to start the treatment of selected patients with a radiotherapy scheme of 26 Gy / 5 fractions in one week, in a controlled manner, through this project.The investigators consider the moment extremely propitious to start the study, as in addition to having the first publication of a large randomized study, proving the effectiveness and safety of the strategy, the investigators will be able to benefit more patients and the health system itself by minimizing the daily visits of these patients at the hospital.

Participants needed: 36
Trial details
Age: 18+Biological sex: FemaleType: InterventionalSponsor: Instituto Brasileiro de Controle do CancerUpdated: Dec 29, 2022Locations: 1
Eligibility criteria

Information to the patient and signed informed consent; [+9]

Previous local irradiation; [+6]

Status: Recruiting

Accelerated Partial Breast Irradiation Versus Standard or Hypofractionated Whole-Breast Irradiation, in Early Breast Cancer, After Breast-conserving Surgery

Radiotherapy has been confirmed as an important treatment breast-conserving surgery reducing the risk of any recurrence of breast cancer and breast cancer-related mortality in patients with early breast cancer. There are no comparative data on the ideal radiotherapy treatment regimen for patients with early stage breast cancer who underwent conservative surgery in the Brazilian population.

Participants needed: 36
Trial details
Age: 50-90Biological sex: FemaleType: InterventionalSponsor: Instituto Brasileiro de Controle do CancerUpdated: Mar 8, 2021Locations: 1
Eligibility criteria

Information to the patient and signed informed consent; [+12]

Previous malignancy (except non-melanomatous skin cancer) [+8]